• 1
    Talley NJ, Jones M, Nuyts G, Dubois D. Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol 2003; 98: 110711.
    Direct Link:
  • 2
    Peppas G, Alexiou VG, Mourtzoukou E, Falagas ME. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol 2008; 8: 5.
  • 3
    Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004; 99: 7509.
    Direct Link:
  • 4
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 148091.
  • 5
    O’Keefe EA, Talley NJ, Zinsmeister AR, Jacobsen SJ. Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Gerontol A Biol Sci Med Sci 1995; 50: M1849.
  • 6
    Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004; 20: 319.
  • 7
    Glia A, Lindberg G. Quality of life in patients with different types of functional constipation. Scand J Gastroenterol 1997; 32: 10839.
  • 8
    Harari D, Gurwitz JH, Minaker KL. Constipation in the elderly. J Am Geriatr Soc 1993; 41: 113040.
  • 9
    Camilleri M, Cowen T, Koch TR. Enteric neurodegeneration in ageing. Neurogastroenterol Motil 2008; 20: 41829.
  • 10
    Bosshard W, Dreher R, Schnegg J, Bula C. The treatment of chronic constipation in elderly people: an update. Drugs Aging 2004; 21: 91130.
  • 11
    Muller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100: 23242.
    Direct Link:
  • 12
    Darlington R. OTC laxatives. J Am Pharm Assoc 1966; 6: 4704.
  • 13
    Voskuijl W, De Lorijn F, Verwijs W et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut 2004; 53: 15904.
  • 14
    Robson KM, Kiely DK, Lembo T. Development of constipation in nursing home residents. Dis Colon Rectum 2000; 43: 9403.
  • 15
    Bassotti G, Gaburri M, Imbimbo BP et al. Colonic mass movements in idiopathic chronic constipation. Gut 1988; 29: 11739.
  • 16
    Briejer MR, Akkermans LM, Schuurkes JA. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995; 47: 63151.
  • 17
    Tonini M, Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis 2006; 24: 5969.
  • 18
    Potet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K+ channel. J Pharmacol Exp Ther 2001; 299: 100712.
  • 19
    Busti AJ, Murillo JR Jr, Cryer B. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004; 24: 52631.
  • 20
    Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 234454.
  • 21
    Camilleri M, Specht Gryp R, Kerstens R, Vanderplassche L. Efficacy of 12-week treatment with prucalopride (Resolor) in patients with chronic constipation: combined results of three identical randomized, double-blind, placebo controlled phase III trials. Gastroenterology 2008; 134: A-548.
  • 22
    Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29: 31528.
  • 23
    Tack J, Ausma J, Kerstens R, Vanderplassche L. Safety and tolerability of prucalopride (Resolor) in patients with chronic constipation: pooled data from three pivotal phase III studies. Gastroenterology 2008; 134: A-530.
  • 24
    Tack J, Van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58: 35765.
  • 25
    Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil 2001; 13: 46572.
  • 26
    Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the patient assessment of constipation quality of life questionnaire. Scand J Gastroenterol 2005; 40: 54051.
  • 27
    Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999; 34: 8707.
  • 28
    Muller-Lissner SA, Fumagalli I, Bardhan KD et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 165566.
  • 29
    Herz MJ, Kahan E, Zalevski S, Aframian R, Kuznitz D, Reichman S. Constipation: a different entity for patients and doctors. Fam Pract 1996; 13: 1569.
  • 30
    Van de Velde V, Ausma J, Vandeplassche L Pharmacokinetics of prucalopride (Resolor) in man [Abstract P0891]. Gut 2008; 57: A282.
  • 31
    Petticrew M, Rodgers M, Booth A. Effectiveness of laxatives in adults. Qual Health Care 2001; 10: 26873.
  • 32
    Dupont C, Leluyer B, Maamri N et al. Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children. J Pediatr Gastroenterol Nutr 2005; 41: 62533.
  • 33
    Pare P, Ferrazzi S, Thompson W, Irvine E, Rance L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001; 96: 31307.
    Direct Link:
  • 34
    De Maeyer J, Lefebvre R, Schuurkes J. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008; 20: 99112.
  • 35
    Briejer MR, Bosmans JP, Van Daele P et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001; 423: 7183.